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ABSTRACT
The concepts of particle engineering and dosage form design
have become dominant themes in pharmaceutical manufac-
turing. This trend is not simply a reflection of the develop-
ment of new, more sophisticated manufacturing methods of
particles or dispersed systems but also recognition of the
importance of quality control even in more traditional manu-
facturing processes. However, the diversity of particle treat-
ments, methods of particle size analysis, expression and
interpretation of data, and process applications results in
complicated and sometimes confusing criteria for selection,
adoption, or relevance of the available techniques.
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INTRODUCTION
A workshop on “Particle Size Analysis” was held in April of
2003 in Washington, DC. This workshop was cosponsored
by the American Association of Pharmaceutical Scientists
(AAPS), the Food and Drug Administration (FDA), and the
United States Pharmacopeia (USP). The intent of the meet-
ing was to provide a forum for debate and exchange of ideas
among academic, industrial, and regulatory pharmaceutical
scientists and equipment manufacturers. Critical process
parameters and their control were identified, and particle size
measurement techniques and statistical comparisons were
reviewed. Particle size specifications and method validation
were also discussed. Knowledge and information were
shared with a view to the preparation of this report.
Pharmaceutical scientists and instrument manufacturers rep-
resenting academia, the industry, and government attended
the workshop. Selection of appropriate particle sizing meth-
ods and the expression of data often seem complex and
apparently subjective activities. The difficulties associated
with approaching particle size analysis extend from solid
dosage forms to dispersed systems. This workshop covered
numerous areas of analysis, from fundamentals of particle
structure and morphology to the characterization and meas-
urement of particle size. Key issues are common to a range
of dosage forms including solids, aerosols, suspensions,
emulsions, liposomes, microspheres, and nanoparticles. The
workshop was divided into presentations on a number of key
issues followed by specific case studies. A review of the
meeting was conducted at its close. The attendees on a
majority vote following discussion approved a bullet point
list of action items. Subsequently, the views of the attendees
were sought by e-mail.
The first day consisted of a review of particle manufacture,
processing, structure, descriptors of shape and size, and sta-
tistical comparison of data. The day concluded with a review
of methods with specific examples described in case studies.
The second day involved a review of the fundamentals of
particle size analysis and its role in the characterization of a
variety of dosage forms, followed by the introduction of
process analytical technology (PAT). On the third and final
day, case studies of particularly difficult particle-sizing
examples were discussed, with particular emphasis on sub-
micron sizing and the influence of shape on analysis.
Throughout the meeting, submitted posters were on display
as were exhibits of particle-sizing instruments.
BACKGROUND
Size analysis of pharmaceutical products and their compo-
nents is highly dependent on variables related to the particles
themselves, the method of sampling, the technique of analy-
sis, and the means of expressing the data. The particles are
susceptible to the influence of manufacturing, processing,
compatibility, storage, and intended use variables. The scale,
context, and method of sampling require consideration to
minimize bias in the particle size estimates. The technique of
measuring characteristic dimensions of the particles inher-
ently dictates the nature of the data collected. In many cases
statistical or mathematical distributions are fitted to the data
as a means of expression, which may predispose the data to
a particular interpretation. The dosage form and route of
administration may necessitate the use of particles with
unique characteristics and the adoption of specialized meth-
ods of analysis. The purpose of this workshop was to
acknowledge the importance of each of these factors and to
provide a forum for debate and discussion for individuals
from all sectors of the scientific community with interest in
pharmaceutical particle size analysis. This report was a
planned outcome of the meeting and is intended to be a use-
ful guide to industry and regulators in pursuit of optimal
approaches to particle sizing for specific applications.
TOPICS
Particle Manufacture and Blending
The origin and history of particles plays a key role in the
interpretation of their analysis. The manufacture and engi-
neering of particles must be considered for a thorough under-
standing of a drug product and its performance. Successful
manufacturing techniques eliminate postcrystallization oper-
ations such as drying and milling. A range of crystallization
methods was outlined including (1) solvent, (2) jet, (3) emul-
sion, (4) supercritical fluid, and (5) spray drying. Unique
dosage forms, such as inhaled aerosols, were identified as
highly dependent on particle size and morphology. Blending
is also highly influenced by the nature of the particles and in
this context real-time analysis may be an important tool.
Crystallization of Polymorphs and Methods of Analysis
Many drugs exhibit polymorphism, which is defined as the
ability to exist in 2 or more crystalline phases that have dif-
ferent arrangements and/or conformations of the molecules
in the crystal lattice. The polymorph with the lowest thermo-
dynamic activity is usually preferred, if bioavailable, owing
to greater stability in solid pharmaceutical formulations. The
relative tendencies of the competing aggregates to grow to
the size of a critical nucleus and subsequently to form a crys-
tal are determined by competing thermodynamic and kinetic
factors. X-ray diffraction (XRD) is the most direct method
for the quantitative and qualitative analysis of polymorphs.
Spectroscopic methods that recognize the differences
between intermolecular interactions among the polymorphs
are also used. Solid-state nuclear magnetic resonance (NMR)
spectroscopy, Fourier transform infrared (FTIR) spec-
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troscopy, and FT Raman spectroscopy are among these
methods. Thermal methods, such as differential scanning
calorimetry (DSC) and hot-stage microscopy, are used to
study phase changes during heating and cooling, while ther-
mogravimetric analysis is used to analyze dehydration or
desolvation. Solubility measurements and solution calorime-
try reveal thermodynamic differences. If the various poly-
morphic forms can be distinguished by differences in crystal
habit, optical techniques including but not necessarily limit-
ed to laser diffraction of light and image analysis (computer-
assisted microscopy) may be used for quantitative analysis of
polymorphs.
Assuming the history and chemical composition and struc-
ture of the particles are known, other morphological features
such as shape and size can be studied. The following sections
outline approaches to evaluating particle shape and size.
Particle Shape Factors and Nomenclature Issues
The measurement and expression of particle size is intimate-
ly bound with the shape and morphology of the constituent
units that make up the ensemble of particles. The difficulties
encountered when relating empirical information derived
using different methods would not exist if the component
particles were spherical. In the real world of pharmaceutics,
particles are rarely (if ever) spherical, and consequently it is
important to understand the importance of particle shape and
morphology. An exposition on the nomenclature for particle
shape and illustrations of the effect of differing types on var-
ious particle size measurements were given. Important qual-
itative descriptors of particle shape were outlined and empir-
ical methods for their determination were discussed.
Statistical Analysis, Equivalence, and Inequivalence: An
Overview of Data Reporting
Some particle size distribution data are mass distributions. A
mass-weighted, rather than number or surface area-weighted,
form is most often the most relevant descriptor of the content
of active pharmaceutical ingredient as a function of particle
size. The implications of defining particle size distribution in
terms of mass weighting were discussed. Statistical methods
of assessing differences or equivalence of mass-weighted
particle size distributions were reviewed. These methods fall
into the categories of stage-by-stage, multivariate, and pro-
files for cascade impactor data obtained when characterizing
aerosol-based formulations.
Particle Size Analysis: A Comparison of Methods
The apparent simplicity of particle size analysis is deceptive.
Particle sizing is a poorly posed problem. Only objects of
simple geometry, namely spheres, can be unambiguously
described by a single numerical descriptor. The size of irreg-
ularly shaped particles is typically expressed in terms of
equivalent spherical diameters. Particle-sizing instruments
use various algorithms based on surface area, volume, or lin-
ear dimension to calculate equivalent spherical diameters.
The various diameters are only identical for spherical parti-
cles. For particles that do not have shapes that significantly
differ from that of a sphere (not long-needles or disks), it is
nonetheless possible to achieve agreement among several
methods. However, there is increasing literature on the effect
of shape on size estimates.
The performance of various particle-sizing instruments was
reviewed. In particular, the performance of the low angle
laser light scattering or laser diffraction was examined and
compared with techniques operating under other principles.
Light scattering instruments may produce artifacts that are
dependent on the instrument (model) and the software
employed. Various number counting methods, despite using
different methods of particle size, in contrast, agree substan-
tially. The causes of artifacts, produced by the Mie-
Fraunhoffer instruments were explored. Assumptions of
sphericity and random orientation may be sources of error for
regular polygons (eg, cubes), plates, or fibers, for example.
Performance verification was recommended as a step to
ensure the accuracy of the measurements in the absence of
artifacts. The usual verification methods often do not fully




Drug delivery via the lungs offers numerous advantages for
the treatment of respiratory diseases, as the drugs are deliv-
ered directly to the site of action. The deposition pattern of
drug aerosols in the lungs is controlled by 3 major factors:
airway geometry, particle size distribution, and the inhalation
flow rate at which the drug is inhaled. The formulation and
device characteristics are the major determinants of particle
size distribution of drug aerosols. Three techniques are wide-
ly employed to determine particle size distribution of inhala-
tion products; namely, inertial diffraction, laser diffraction
analysis, and time-of-flight particle sizing (TOF). Impactors
have been used extensively and are the instruments of choice
for the determination of aerosol mass size distribution. The
impactor consists of multiple stages that are held together to
prevent air leakage. Each impactor stage contains multiple
precision-drilled orifices. When air is drawn through, the
impactor particles are projected toward the surface of a col-
lection plate. The range of particle sizes collected on each
stage depends on the jet velocity and the cut-off diameter of
the previous stage. At each subsequent stage, the orifice sizes
are smaller, thereby increasing the linear velocity of parti-
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cles, their inertia, and the opportunity to collect them as a
function of their size. Submicron particles that pass the last
stage are collected on an absolute filter. There is a link
between the cut sizes of individual impactor stages and the
likely deposition sites in the respiratory tract of the particles
that are size-separated. However, it is important to appreciate
that the constant flow rate through a cascade impactor does
not simulate the continuously varying flow rate associated
with the respiratory cycle. Therefore, the inertial classifica-
tion method should be used for in vitro characterization of
inhalation aerosols. Laser diffraction was originally
employed to evaluate populations of liquid droplet sizes but
is now often used for dry powder aerosol characterization. In
classical laser diffraction, an expanded laser beam is used to
produce a parallel beam of coherent, monochromatic light. A
Fourier transform (range) lens is used to focus the diffraction
pattern generated by the collection of particles entering the
measurement zone onto a multi-element photodetector array
located in the plane orthogonal to the incident light, at a focal
distance from the range lens. The angle of scatter is a func-
tion of particle size and summing from each of the detectors
allows the distribution to be reconstructed. The measurement
is quick but does not employ a chemical detection method
and only samples the aerosol plume. Time-of-flight instru-
ments operate on the principle of accelerating particles in
ultra-Stokesian flow. The time-of-flight of individual parti-
cles is longer than for a particle of infinitesimal mass that
would move with the accelerating fluid and is related to aero-
dynamic particle size. The instrument provides a direct meas-
urement of the aerodynamic size distribution. Again this
method does not discriminate between particles of different
composition. Co-incidence errors may occur as a result of
incomplete separation of particles.
Parenterals
Stable drug nanosuspensions for intravenous (IV) injection
are typically prepared using a proprietary microprecipitation
and/or homogenization process. These preparations were
shown to possess significantly reduced acute toxicity as com-
pared with the commercially available IV drug solution prod-
uct. In the example discussed, each nanosuspension was pre-
pared using a proprietary technique combining comminution
of solid drug raw material with particle coating. The particle
coating was carried out using surface-active coating agents
that consisted of a combination of conventional ionic and
nonionic surfactants at low concentrations. Solvent/surfac-
tant residue in the finished product met International
Conference on Harmonization (ICH) guidelines. No wear
metal contamination was detected. Representative nanosus-
pensions used in preclinical animal studies were tested for
pyrogenicity using the standard United States Pharmacopeia
(USP) rabbit test and were nonpyrogenic. Both thermal ster-
ilization and aseptic processing were successfully demon-
strated. Particle size distribution is an important physical sta-
bility parameter.
Instrumental particle-sizing equipment manufacturers often
recommend but do not provide specific methodology in cor-
relating imaging and instrumental analytical results. Most
often consistent results between the 2 methods can only be
achieved with spherical and narrow-size distributed particles.
For plate-like drug solid in nanosuspension, population
instrumental analysis techniques remain the only practical
option for the determination of suspension particle size dis-
tribution. However, instrumental particle sizing results can
be influenced by a number of factors (eg, refractive index). A
matrix approach has been initiated to correlate results from
different instruments using various particle-sizing principles.
In addition, an approach to use 2-dimensional scanning elec-
tron microscope (SEM) photographs of large particles for the
calculation of 3-dimensional, equivalent volume sphere
diameters has been performed. The combination approach
has the potential to appropriately report particle size distribu-
tion using an instrumental particle-sizing method.
Perspective on Optimizing Particle Size to Improve
Performance of Oral Immediate Release Tablets
A decision tree for optimization of the particle size of drug
substance for an oral dosage form was outlined (see Figure
1). A discussion was then presented on the effects of particle
size on absorption properties. Small particles with large sur-
face area gave higher peak plasma concentration and
bioavailability and reduced time to peak plasma concentra-
tion. There was further discussion on the effect of hydrody-
namics, wetting, and the presence of surfactant on dissolu-
tion. It was concluded that particle size may significantly
affect oral absorption of a compound. Dose required, solubil-
ity, and permeability are important parameters for predic-
tions. Several factors such as fed or fasted state, gastrointesti-
nal hydrodynamics, wetting, etc, may affect oral absorption
from different particle sizes; however, more research is
required and better models are needed for further study.
Other particle attributes, such as density and morphology
may have significant effects on material properties and tablet
attributes.
Particle Size and Blending
Drug particle size has a critical effect on the content unifor-
mity of solid dosage forms, where poor content uniformity
would result if a drug powder were not dispersed evenly
throughout a mixture with excipients. A leading cause of
poor content uniformity is a mismatch of drug and excipient
particle size and density leading to segregation during sam-
pling and manufacture, especially for low drug to excipient
ratio blends. However, the focus of this presentation was to
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discuss perhaps a less obvious cause of poor content unifor-
mity: a particle size distribution of a drug too large to achieve
content uniformity even when all of the aforementioned
causes have been addressed. The concept of ideal mixing was
presented to demonstrate that poor content uniformity result-
ed, even with ideal mixing, if the drug particle size distribu-
tion was too large. Using the ideal mixing analysis, an edge
of failure between a particle size distribution that will cer-
tainly cause poor content uniformity and one that is con-
ducive to good content uniformity can be established.
Approaching the upper edge of failure in terms of drug par-
ticle size may be desirable, since reducing the particle size
too dramatically can exacerbate the problems of drug
agglomeration and mixing. The goal of the presentation was
to provide a scientific rationale for setting a drug particle size
specification that is conducive to content uniformity before
expensive and time-consuming formulation development
begins. Simulations of content uniformity assuming ideal
mixing were compared with experimental content uniformi-
ty data as validation of analysis.
Process Analytical Technology, Specification, and
Comparisons: FDA Perspectives
Initiatives from the FDA Office of Pharmaceutical Sciences
were described that focus on optimizing pharmaceutical
process quality. Current FDA initiatives on science and tech-
nology focus on process analytical technology (PAT). This
involves process analytical chemistry, in- and on-line tools,
and multivariate and pattern recognition methods. The appli-
cation of these technologies provides the opportunity to
move from testing to assess product quality to continuous
quality assurance. Following in the footsteps of W. Edwards
Deming quality systems will reduce process variability and
thereby ensure product quality and performance characteris-
tics. The development process and science behind a product
are not generally shared with the FDA, therefore manufactur-
ing processes and controls have the appearance of art and not
science. Research and development is conducted in a high
technology environment and manufacturing is often low
tech. The barrier between the FDA and industry leads to both
a poor interchange of data and a poor understanding of qual-
ity and process design. Material property characterization
and process simulation encompass clear disciplines from
physical chemistry to engineering physics. The PAT initiative
of the FDA will advance pharmaceutical science and manu-
facturing efficiency. The Science Board of the FDA is very
supportive of PAT. A training curriculum for FDA staff and
regulatory framework are proposed. The FDA intends to
improve the knowledge base for technical policy develop-
ment. The overall goal of these pursuits is to develop a drug
quality system for the 21st century. This requires up-to-date
concepts of risk management. Submission, review and
inspection should be coordinated. To define the desired state
requires a shared vision from all stakeholders highlighting
the science of process engineering and common good manu-
facturing practices (cGMPs) for the 21st century. Regulatory
policies should be tailored to recognize the level of scientif-
ic knowledge of manufacturing processes. The impact on
product manufacturing and performance will result in quali-
ty by design.
Impact of Particle Size on Product Performance:
Chemistry, Manufacturing, and Controls (CMC Issues)
Particle size derives from physical properties, manufactur-
ing, processability, and quality attributes. These factors
determine in vitro and in vivo performance.
A number of examples were given including controlling
extended release in tablets through sieving, which failed due to
particle size effects. Dissolution would have predicted this
phenomenon. The importance of particle size in the therapeu-
tic effect of inhalation products renders clinical bioavailability
and bioequivalence potentially irrelevant. Liposomes require
control of vesicle size to ensure predictable therapeutic target-
ing, dose delivery, pharmacokinetics, and pharmacodynamics.
The regulatory considerations of importance are the factors
controlling particle size. Management of stages at which testing
is required and establishing targets and specifications on parti-
cle size should be a priority. The methods employed include
Figure 1. A decision tree for recommending particle size
(PS) of drug substance.
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validated sampling techniques with instruments/detectors
selected for the application with a relevant detection/measure-
ment range and establishment of acceptance criteria. On-line
determinations are desirable (eg, near infrared or Raman spec-
troscopy).
It is prudent to understand the principles effecting perform-
ance, which can be viewed in terms of quality, safety, and
efficacy as depicted in a triangle or Venn diagram.
Measurement and Interpretation of Particle Size
Distribution
Particle size determination involves both measurement and
modeling in the context of process engineering. A matrix
approach is required, which encompasses process, product,
design, and control.
Sampling continues to be a source of error and concern in
pharmaceutical processes. However, in the broader field of
powder handling and production this may be a thing of the
past. Most techniques are considered for their value off-line,
on-line, in-line, or in situ with a view to continuous process
control. The specifications (acceptance criteria) should dic-
tate process control or the manner in which the particle size
distribution curve is interpreted.
Particle sizes are usually viewed in terms of geometrical (eg,
spherical surface, volume, etc) or behavioral (eg, sedimenta-
tion) equivalence. There is a need for written and physical
standards for calibration of all particle-sizing methods. This
includes size (monodisperse, polydisperse) and refractive
index (eg, Japanese, International Fine Particle Research
Institute [IFPRI]) standards. These standards should be
reproducible, sensitive (for product control), and accurate, if
absolute particle size is important. Shape is a factor that also
influences calibration of almost all particle-sizing instru-
ments and should also be the subject of investigation.
Light-scattering methods may be divided into single particle
versus population analysis methods. The point was made that
5 instruments may give the same distribution but will appear
different based on the algorithm used for normalization. In
effect, current instruments can “iron out” differences. Since
image analysis and light scattering are complementary meth-
ods, it was suggested that they could be combined into a sin-
gle instrument.
Analysts were exhorted to define the question they wish to
have answered. It was suggested that manufacturers are in a
position to produce instruments that are capable of address-
ing the question once it is posed.
Parenterals: Methods of Analysis and Data Interpretation
The history and standards for foreign particulate matter in
injectable products were reviewed. In 1963, Garvan and
Gunner published an article on extraneous particulate matter
in injectable products that got the attention of regulators and
industry. Industry practices have steadily improved since the
late 1960s. In concert, compendial and regulatory standards
have also been tightened and harmonized. Methodology has
also improved over the years. Foreign particulate matter in
parenterals comes from both intrinsic and extrinsic sources.
Detection of particles is normally achieved by visual, micro-
scopic, electrical resistance, or light obscuration techniques.
Compendial methods and standards have existed since 1973
(British Pharmacopeia [BP]) and 1975 (USP). Standards
were harmonized among the United States, Japanese, and
European Pharmacopeias in 1998 for both small and large
volume parenterals. Working with Pharmaceutical Research
and Manufacturers of America (PhRMA), USP is also devel-
oping foreign particulate standards for ophthalmic solutions.
Particle Size Analysis and Its Role in Pharmaceutical
Development
Aerosols
Delivery of medications as aerosols to the lungs is an excel-
lent route of administering topical treatment as well as target-
ing other organs via the blood circulation. However, the res-
piratory tract is size-selective, in that larger particles are pro-
gressively removed from the inhaled air stream as they pass
via the mouth, larynx, and bronchial airways toward the alve-
olar spaces in the lungs. The need to use techniques in the
laboratory that measure the particle size of inhaled aerosols
is therefore self-evident. Two distinct pathways for the use of
the data are apparent when evaluating methods for particle
size analysis. On the one hand, the manufacturer of the for-
mulation needs to have reliable, accurate, and reproducible
methods that meet the needs for product development and
quality control. It is also important to understand how the
aerosol is likely to behave in the respiratory tract. This path-
way has resulted in developments in laboratory-based meas-
urements that attempt to provide greater predictability for
deposition behavior. Reference methods defined in the
Pharmacopeias are based on inertial impaction; although
often time-consuming, these methods have the advantage of
having been validated successfully in many laboratories.
They are also based on direct chemical assay for the mass of
active ingredient (API). Aerodynamic particle size distribu-
tion data are determined, taking into account both particle
shape and density, and therefore predictive of transport
through the respiratory tract. Recent developments have
included the integration of impactors and breathing simula-
tors as well as the development of entry geometries that more
closely simulate the upper respiratory tract. Newer tech-
niques that incorporate optical-based particle sizing have the
potential to enhance productivity greatly, since measure-
ments are often made in real-time and may not require the
The AAPS Journal 2004; 6 (3) Article 20 (http://www.aapsj.org).
7
aerosol to be sampled. However, since direct assay for API is
not performed, these measurements should ideally be sup-
ported by data from more traditional methods.
Parenterals and Extrinsic Contamination: Quantifying
Instability and Incompatibility
The extemporaneous preparation of intravenous dosage forms
is a difficult task and should ideally be performed by qualified
pharmacy personnel under laminar airflow conditions, and in
a dedicated compounding environment to ensure the sterility
and integrity of the final parenteral admixture. Although
sterility may be achieved under these conditions, the introduc-
tion or generation of rigid particulates (crystals, fibers, glass,
elastomeric enclosures, coprecipitates, etc), or the production
of abnormal dispersions, containing enlarged fat globules
from the coalescence of lipid emulsions, must also be avoid-
ed whenever possible. A prime example of the most complex
intravenous dosage form extemporaneously prepared on a
daily basis that poses such risks is a parenteral nutrition (PN)
admixture. As many as 50 or more chemical entities comprise
the typical PN formulation, which are often made with the aid
of an automated compounding device that may be a signifi-
cant source of particulate contamination. In addition, PN
admixtures contain potentially incompatible combinations of
electrolytes routinely prescribed such as calcium and phos-
phate salts. Lipid emulsions may also be added that may
become unstable during the period of infusion. The use of in-
line filters will reduce the exposure of both rigid and flexible
particles entering the bloodstream and are recommended for
all PN admixtures. Other filtration devices, such as filter nee-
dles, will also reduce exposure to glass fragments when
ampoules are used. Evidence supporting these claims has
been quantified by measuring the presence of particulates or
unstable fat globules using light obscuration that has been
almost exclusively applied to pharmaceutical manufacturers




A historical perspective on aerosol testing and the perceived
limitations were reviewed. A summary was given of the FDA
Draft Guidance for use of impactors, particle size distribution
(PSD), drug recovery, minimum number of actuations, char-
acterization of PSD, and expectation of width of stage group-
ings were discussed. It was concluded that specifications for
particle size distributions are set around groupings of size
fractions. Groupings are product specific and strength specif-
ic. Stage deposition remains the most desirable method of
defining sampling data. Variability in critical dimensions
(principally stage nozzle diameter) in cascade impactors is a
significant source of variation in PSD measurement.
Initiatives to understand the effect of stage nozzle diameter
variation on impactor-measured size distribution data are
being considered by expert groups, such as the European
Pharmaceutical Aerosol Group (EPAG).
Nasal
While particle size must be controlled to a narrow size range
for optimal targeted deposition in the lower respiratory tract,
the particle size requirements for nasal deposition are far less
stringent. One of the primary physiologic functions of the
nose is to clean inspired air. As a result, most particles larger
than 0.5 µm have a probability of depositing within the nasal
cavity following inhalation through the nostrils. In general,
particles larger than 10 µm are collected with greatest effi-
ciency in the nose. The anatomical arrangement of the nasal
cavity is designed to trap particulate matter to limit its entry
into the lungs. The airways in the nasal cavity are narrow
spaces that pass between several scrolls of mucosal tissue
extending into the cavity from the lateral walls or between
the surface of these extensions (turbinates) and the nasal sep-
tum. The narrow air spaces, along with the turbulent air flow
patterns result in the inertial impaction of most particles that
enter the nose. In addition to the narrow airspaces within the
nasal cavity, the physical narrowing of the airway posterior
to the nostrils, a region referred to as the nasal valve, results
in most of the particulate impaction occurring within the
lower one third of the nose. Because of these anatomical bar-
riers, a major challenge in drug delivery to the nasal cavity is
designing spray, aerosol, or powder systems whose particles
remain in the air stream, pass through the nasal valve, and
subsequently deposit within the main nasal cavity. Important
parameters to consider include particle size, density, particle
and inspiratory air stream velocity, nasal cavity resistance,
and the shape of the spray emitted from the delivery device.
Studies using an in vitro model of the nasal cavity have
shown that spray angles in the range of 20° to 30° result in
the maximum deposition of a spray beyond the nasal valve.
Solids
Powder flow depends directly on cohesive strength of the
mixture, which is a nonlinear function of particle size and
blend density. Blend bulk density is directly affected by
cohesion. Hardness is a function of the number of interparti-
cle contacts. Compressibility is a direct function of bulk den-
sity. Disintegration by capillary wetting is affected by pore
size, which is directly related to particle size. Dissolution is
enormously dependent on surface area. Content uniformity is
affected by particle size in many ways. In the context of
process analytical technology it is necessary to first under-
stand materials, products, and processes, and then design the
monitoring method. The present approach (ie, place the sen-
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sor in the process, collect data, and then maintain “consisten-
cy”) raises a number of questions, such as the following:
• What should be measured?
• How should it be measured (with what error)?
• How will the data be interpreted (what do they
mean)?
• What is their statistical significance?
• How can the data be applied?
Finally, how is the calibration affected by the analytical
method? Most spectroscopic techniques require calibration,
which is typically performed on fresh material. However,
conventional pharmaceutical processes deeply affect the
materials being examined.
Parenterals
In research, development, and manufacture it is important to
determine not only the mean or average particle size but also
the entire size distribution in order to fully understand the
system. A case was presented on emulsion systems that have
undergone accelerated stability testing to show how particle
size distribution can be used as a predictor of accelerated sta-
bility, as well as an indicator of the destabilization mecha-
nism. Oil-in-water emulsions were subjected to elevated
temperatures. There was no significant change in the mean
particle size of these emulsions; however, the particle size
distribution changed with time, indicating that Ostwald
Ripening was occurring. The data were analyzed according
to the Lifschitz, Slezov, and Wagner (LSW) theory, which
confirmed that Ostwald Ripening or coalescence was the
dominant emulsion destabilization mechanism.
Challenges in Particle Sizing of Submicron Dispersions
Nanocrystal technology is a formulation and manufacturing
approach used to enhance the performance of poorly water
soluble drugs. One element of the technology involves
milling dispersions into submicron-sized colloidal suspen-
sions, typically in the range of 100 to 400 nm. The ability to
accurately determine the particle size distribution of these
suspensions is essential in order to understand their physico-
chemical behavior as well as to control and transfer the man-
ufacturing process. Light scattering was the method of
choice for reasons of expediency and ease of measurements.
While modern instrumentation has greatly simplified the task
of measuring particle size distributions, it is still important to
critically evaluate both accuracy and precision of the results.
The same sample analyzed on different instruments more
often than not produces different results. Several examples of
variability between different brands and models as well as
between individual units of the same brand were presented.
In addition, a comparison between static and dynamic light
scattering as it pertained to their individual formulations was
presented.
Size Characterization of Submicron Suspensions
Nanosuspensions, such as those prepared by precipitation or
processing, present technical challenges to those seeking to
characterize the resulting size distributions and/or the parti-
cles themselves. While the small dimensions involved form
one aspect of the problem, another arises from the fact that
frequently there is as much interest in the low number popu-
lation present at diameters greater than 1 µm as there is in the
rest of the distribution. The interest in this form of polydis-
persity can be due to concerns of safety or in vivo perform-
ance, or from the mechanistic information that their presence
tells the investigator about the process by which the nanosus-
pension was formed. Technical concerns result from the fact
that many of the available methods do not always successful-
ly span size distributions straddling the interval near 1 µm
either because this value represents a limit to the range of the
method, such as Fraunhofer diffraction or dynamic light scat-
tering, or because of limitations in dynamic range, as is the
case with counting techniques. This is in addition to the dif-
ficulty of observing a small number of larger particles in the
presence of a much greater quantity of smaller particles.
Multiple techniques, based upon different physical phenom-
ena, are thus required if the desired understanding is to be
obtained. Almost invariably, the situation is vastly simplified
when project-specific needs and goals are detailed and
understood before the analytical solution is designed.
Illustrative examples in which methods based on counting
(eg, single-particle counting, microscopy), spectroscopy (eg,
light scattering, turbidity), and visual assessment were used
to answer specific questions regarding processed and precip-
itated nanoparticles. In one example, these approaches were
used to elucidate the relationship between processing and
oral absorption, and in another, they were used to determine
the suitability of a nanosuspension to intravenous or oph-
thalmic administration. A third example demonstrated the
feedback that size characterization provides to the production
of polymeric nanoparticles. Novel enhancements to measure-
ment science such as the use of fiber-optic probes in light
scattering were also discussed.
Determining Particle Size Specification for a Poorly Water
Soluble, Needle-Shaped, Crystalline Active in an Oral
Product
Setting a particle size specification for the active ingredient
is necessary for oral drugs with poor aqueous solubility. Most
particle size analysis techniques are accurate in determining
the “representative diameter” of a population of relatively
spherical particles. For nonspherical particles, accurate deter-
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mination of a single “representative diameter” is a luxury.
Rather, an analysis technique that gives reproducible “repre-
sentative diameter” should be selected. The drug described
was poorly water-soluble with needle-shaped crystals. The
drug product was an immediate-release oral capsule. The
objective was to determine the drug particle size specifica-
tion that resulted in a desirable dissolution profile range.
Different particle size analysis techniques were evaluated
and a laser light scattering (LLS) technique was selected to
measure volume-averaged diameter, the most relevant “rep-
resentative diameter” for this type of drug. Three diameters
were used to characterize the particle population: d(v,0.1)
10th percentile diameter; d(v,0.5) 50th percentile diameter;
and d(v,0.9) 90th percentile diameter. Since the active is nee-
dle shaped with a broad size distribution, all 3 particle diam-
eters were evaluated for their effect on in vitro dissolution
rate. Active ingredients with d(v,0.5) ranging from 2 to 75
µm were prepared and in vitro dissolution of the correspon-
ding drug product tested. The dissolution test was a USP bas-
ket method using surfactant in the medium with 15, 30, 45,
and 60 minute test points. Dissolution specification for the
drug product is set on the percentage of drug dissolved at 60
minutes. A plot of particle size with percentage drug dis-
solved at 60 minutes indicates a very high linear correlation
between dissolution and 2 of the diameters at the 15th and
19th percentile. Correlation between drug dissolution at 60
minutes and d(v,0.1) was very poor. Based on the linear cor-
relation and the desired range of percentage of drug dis-
solved at 60 minutes, the active ingredient particle size spec-
ification was set on the 2 diameters of most significance:
d(v,0.5) and d(v,0.9).





Silicon micromachined cube/cuboid particles were developed
by Professor Paul Kaye (University of Hertfordshire, UK) and
3 shapes were certified as standards by AEA Technology
(Dorchester, UK) in the mid 1990s as part of the UK Valid
Analytical Measurement (VAM) program. In 2000, they were
available as certified reference materials (CRMs) as AEA-
1001, AEA-1002, and AEA-1003 through the Office of
Reference Materials, Laboratory of the Government Chemist,
Teddington, UK. The AEA 1001-1003 standards can be pur-
chased from LGC Promochem, Teddington, UK (www.lgcpro-
mochem.com). Other particle shapes have been made by con-
trolled crystal growth following techniques developed by Egon
Matijevic and coworkers in the 1980s; however, to date no
CRMs or standard reference materials (SRMs) have been
developed. The lack of standard reference materials has been
discussed elsewhere.1
1.1.2 Refractive Index
IFPRI standards have well-defined, real, and imaginary
(absorption) components of refractive index and are manufac-
tured in different size ranges. Whitehouse Scientific (Chester,
UK) [http://www.whitehousescientific.com/] has manufactured
so-called “mirror” standards of the nonabsorbing particles.
These have the same size ranges and were size characterized by
several laboratories using a range of traceable methods in a
consensus-based exercise in preparation for certifying the
IFPRI materials. These mirror standards are readily available
but would need to be adopted by a national standards body to
officially reach CRM/SRM status. (IFPRI, Dr. Brian Scarlett,
University of Florida, Gainesville, FL has these standards.)
1.1.3 Nanoparticles – Need standards for these – ie,
physical particles
NIST already has a monodisperse 100 nm SRM available
(SRM 1693, 101 ± 2 nm). It would be desirable to obtain
other nanoparticle standards, eg, 20 and 50 nm SRMs.
1.1.4 Multimodal – Use 2 or 3 standards to show
instrument discriminates – include uniform
polydisperse distribution
So-called “cocktail” mixtures containing 3 monodisperse
subfractions in well-defined proportion were produced as
CRMs by AEA Technology in the mid 1990s as part of the
VAM program (see 1.1.1). The sizes, based on volume equiv-
alent diameter were: AEA-1004 : 0.1, 0.2, 0.5 µm; AEA-
1005 : 0.2, 0.5, 1.0 µm; AEA-1006 : 0.5, 1.0, 2.0 µm; AEA-
1007 : 1.0, 2.0, 5.0 µm. Again, their current status is uncer-
tain, but the technology has been proven, should there be a
desire to remake these materials.
1.1.5 Recommendation – Formal request to National
Institute of Standards and Technology (NIST)
and include other potential users
The meeting indicated that any request to NIST will need to
indicate broad-based consensus for particular SRMs across
industry sectors. In the opinion of some, given that IFPRI
already has broad-based support, the development of SRMs
based on their refractive index (RI) standards would seem to
have the greatest chance of success. There is a perceived need
to bring together a group of opinion leaders within industries
in which particle sizing is important (fine chemicals, pig-
ments, foodstuffs, etc) as well as the pharmaceutical sector, to
promote the development of the most needed CRMs/SRMs.
1.2 Written Standards (American Society for Testing
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and Materials [ASTM], International Organization
for Standardization [ISO])
Include European Committee for Standardization (CEN) and
National Standards (eg, Canadian Standards Association). A
strong desire was expressed to have International
Organization for Standardization (ISO) standards eventually
supersede national written standards.
2 Shape
2.1 Instrumentation – Appropriate instrumentation (eg,
SEM or microscopy) allows you to choose appropri-
ate instrument. Get data and how do we turn that into
a shape (algorithm). Since shape-related effects may
bias many particle size analysis techniques,
microscopy should always be used as a check for
particle size. Combined with automated image
analysis, microscopy can give an idea of the size dis-
tribution based on appropriately chosen projected
dimensions that take into account particle shape.
2.2 Error – Some techniques (eg, if calculated, equiva-
lent spheres will give inherent error in measurement)
need complementary method(s) to deconvolute
shape factors. Also, real time aerodynamic particle
size analysis by methods based on the time-of-flight
principle are known to have a significant shape-
related bias that is not apparent in the reported data
that is scaled to aerodynamic diameter.
3 Sampling and Sample Preparation
3.1 Can we make on-line methods available – Samples
in motion (minimizes discrete sampling inadequa-
cies), process control (PAT). How to do particle siz-
ing and particle characterization on-line (near infra-
red [NIR], etc)?
3.2 Need recommendation on best thief and sampling
practices – Sampling should ideally be from a mov-
ing stream. Recognizing that this is not always pos-
sible: what methods for the use of thieves should be
adopted?
3.3 Process control endpoints – eg, blending until ana-
lytically determined endpoint
3.4 If not bolus sampling, use isokinetic methods –
Recommend use of bolus sampling




4.2.2 How to determine degree of agglomeration and
techniques to disperse
5 Similarity – The Need to Understand Materials
5.1 How do characteristics affect performance?
5.2 History of product
5.3 Address how specs are set when vendor and manu-
facturer have different methods
6 Comparability “Complementarity” of Methods – How
you choose to express the data: all relevant data should be
presented
6.1 Product specificity – method selection/method suit-
ability
6.2 Describe how calculations are performed
6.3 Know the limitations of your instrument
7 Expression of Data – What are the methods detecting?
7.1 Needs, complete information
7.1.2 All methods
7.1.3 Complete size distribution
7.1.4 Multivariate analysis may be preferable
7.2 Definitions for expressing data
There is a need for a standardized set of definitions to express
particle size data and the parameters that are derived to
describe central tendency, spread, and so on, of the distribu-
tion data. The present situation is highly confusing, given
both the differences in weighting that are obtained from dif-
ferent techniques and the multiplicity of size distribution
parameters that exist.
8 Validation
8.1 Alternative approaches needed if you cannot cali-
brate (eg, if using spheres to calibrate and they are
not relevant to the particle shape).
8.2 Cascade impactor calibration is particularly impor-
tant.
Recognizing that it is not current practice to calibrate
impactors with monodisperse particles on a routine basis, the
US compendia allows a procedure called “stage mensura-
tion,” whereby the critical stage nozzle diameter(s) are meas-
ured at user-defined periods of time, to identify wear and/or
corrosion. Cascade impactor performance verification is par-
ticularly important in relation to measurement of aerosol par-
ticle size distributions. Currently, there is no established rela-
tionship between stage nozzle diameter (mean diameter for
multi-nozzle stages) and stage cut size. Stage mensuration,
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recommended in the US compendia, thus provides data that
cannot be readily related to changes in impactor perform-
ance. Calibration with monodisperse particles provides a
direct indication of changes to stage cut sizes with use but is
extremely time consuming and labor intensive to perform.
There is, therefore, a need to develop a more suitable
approach for routine performance verification, and methods
that are based on measurement of pressure drop at a fixed
flow rate may offer some potential in this respect and should
be explored with urgency.
9 Suitability of Methods for Different Systems (dosage
forms, particles versus emulsions)
9.1 Some methods may distort data for certain systems;
for example, using liquids with microscopy.
10 Absolute Particle Size Versus Something Relevant for
Quality Control (impaction-mass on stages)
10.1 Complete understanding of your instrument is
important
10.2 Instrument comparison of data output is needed (sig-
nal output)
There may be some caveats with regard to the importance of
these items. In the aerosol measurement field, combination
of cascade impactor stages to provide an indication of total
mass contained in the therapeutically relevant portion of the
emitted mass from the inhaler is routinely undertaken by sev-
eral organizations, particularly for quality control purposes.
It is not clear that all of the meeting attendees would regard
this issue as low priority. The development of robust
approaches that reduce the number of samples required for
assay is a significant advantage in this context, which may
also be the case for other dosage forms where multi-stage
particle size analysis is necessary.
11 Statistical Considerations for Data Interpretation
11.1 Sameness
The development of criteria for defining product similarity
based on particle size analyses will necessitate agreeing
methodology for both the measurement and interpretation of
size distribution data.
11.2 Use statistical approaches for instrument data output
comparisons – Permits removal of algorithms.
12 Prospective Versus Retrospective Analysis
12.1 Since we know the characteristics, we can predict
performance.
ACTION ITEMS
• Recommend FDA consider – Guidance, PAT
• USP consideration – Written standards
Note – USP currently preparing monograph on laser
diffraction








Impact of particle size on stability 
Impact on bioavailability 
Other ideas? 
• Working group: Product Quality Research Institute
(PQRI), IPAC, European Pharmaceutical Aerosol
Group (EPAG), AAPS Focus Group should be
formed, etc.
Attendees should consider other relevant groups that might
consider issues raised at the workshop. PQRI has issued one






• Are there other industry models for these activities?
• Continued participation by attendees is expected.
CONCLUSION
The improvement of currently accepted methods for particle
size analysis of pharmaceutical products will require ongo-
ing participation by those involved with this activity. The
meeting participants identified many groups whose primary
activity is to review and to develop relevant methods and
standards for particle size analysis for pharmaceutical prod-
ucts. Recognizing this ongoing effort, many of the action
items involve bringing the opinions of the group to the rele-
vant agencies. A second meeting was proposed that would
occur at a defined period following the first meeting (2
years) to review the effect of the action items, and the pas-
sage of time, on industry and regulatory practice. At that
time (spring 2005), we encourage the AAPS to consider set-
ting up a Focus Group to act as a vehicle for those interest-
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ed to follow up on the action items identified by this
Workshop. Currently, particle-sizing issues are discussed
with respect to the relevant dosage form in the various cur-
rently standing AAPS Focus Groups, but as was clear from
this meeting many of the issues are common to several if not
all dosage forms. Serious consideration should be given to
this or a similar initiative, if the outcomes from the
Workshop are not to be dissipated when other priorities take
precedence in the activities of the attendees and their spon-
soring organizations.
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